Bio-Path Holdings, Inc.
Index- P/E- EPS (ttm)-1.96 Insider Own0.43% Shs Outstand7.96M Perf Week-11.46%
Market Cap11.25M Forward P/E- EPS next Y-1.68 Insider Trans0.00% Shs Float7.93M Perf Month-21.91%
Income-14.00M PEG- EPS next Q-0.47 Inst Own5.80% Short Float / Ratio0.81% / 1.75 Perf Quarter-8.55%
Sales- P/S- EPS this Y45.10% Inst Trans11.40% Short Interest0.06M Perf Half Y-56.59%
Book/sh2.26 P/B0.62 EPS next Y8.70% ROA-62.20% Target Price11.00 Perf Year-63.99%
Cash/sh1.69 P/C0.82 EPS next 5Y- ROE-67.20% 52W Range1.27 - 4.48 Perf YTD-7.95%
Dividend- P/FCF- EPS past 5Y36.10% ROI- 52W High-68.96% Beta1.37
Dividend %- Quick Ratio8.20 Sales past 5Y- Gross Margin- 52W Low9.17% ATR0.12
Employees10 Current Ratio8.20 Sales Q/Q- Oper. Margin- RSI (14)35.33 Volatility8.18% 7.68%
OptionableYes Debt/Eq0.00 EPS Q/Q-67.90% Profit Margin- Rel Volume2.75 Prev Close1.71
ShortableYes LT Debt/Eq0.00 EarningsMar 31 BMO Payout- Avg Volume36.70K Price1.39
Recom2.00 SMA20-12.10% SMA50-23.96% SMA200-48.18% Volume100,786 Change-18.71%
Mar-11-21Initiated ROTH Capital Buy $13
Nov-13-17Reiterated H.C. Wainwright Buy $4.50 → $1.50
Aug-10-16Reiterated Maxim Group Buy $5 → $2
Apr-18-16Initiated Rodman & Renshaw Buy $5
Jun-02-14Resumed Maxim Group Buy $5
May-09-14Initiated Maxim Group Buy $5
Mar-31-23 07:00AM
Mar-24-23 04:01PM
Mar-16-23 07:00AM
Dec-28-22 09:59AM
Dec-07-22 07:00AM
07:00AM Loading…
Nov-15-22 07:00AM
Nov-08-22 07:00AM
Nov-07-22 07:00AM
Oct-24-22 07:00AM
Oct-23-22 09:36AM
Sep-30-22 11:24AM
Sep-06-22 07:00AM
Aug-16-22 07:00AM
Aug-09-22 07:00AM
Jun-13-22 12:10PM
07:00AM Loading…
May-17-22 07:00AM
May-16-22 07:51AM
May-10-22 07:00AM
Apr-13-22 04:30PM
Apr-12-22 04:01PM
Apr-06-22 07:00AM
Mar-11-22 07:00AM
Mar-08-22 04:30PM
Mar-04-22 07:00AM
Jan-05-22 07:00AM
Dec-13-21 07:00AM
Dec-06-21 04:22AM
Nov-12-21 07:00AM
Nov-05-21 08:00AM
Nov-04-21 09:01AM
07:00AM Loading…
Oct-27-21 07:00AM
Sep-20-21 04:30PM
Aug-25-21 10:24AM
Aug-24-21 11:00AM
Aug-13-21 07:00AM
Aug-06-21 07:00AM
Jun-22-21 07:00AM
Jun-15-21 03:22PM
Jun-09-21 01:56AM
May-27-21 08:00AM
May-14-21 07:00AM
May-07-21 07:00AM
Apr-26-21 09:00AM
Apr-22-21 07:00AM
Apr-12-21 07:00AM
Apr-05-21 08:03AM
Mar-11-21 07:00AM
Mar-10-21 07:00AM
Mar-03-21 04:01PM
Feb-18-21 04:01PM
Feb-16-21 07:15AM
Feb-13-21 07:00AM
Feb-10-21 07:08AM
Dec-21-20 02:05PM
Dec-11-20 03:48AM
Nov-19-20 07:00AM
Nov-13-20 07:00AM
Nov-06-20 08:00AM
Oct-22-20 07:00AM
Sep-18-20 12:00PM
Sep-09-20 08:00AM
Aug-14-20 07:00AM
Aug-13-20 07:00AM
Aug-07-20 08:00AM
Jun-25-20 11:28PM
Jun-17-20 07:30AM
May-29-20 08:00AM
May-15-20 07:00AM
May-13-20 05:00PM
May-08-20 08:00AM
Apr-27-20 09:00AM
Apr-13-20 07:00AM
Mar-13-20 07:39PM
Mar-11-20 07:00AM
Mar-06-20 07:00AM
Feb-28-20 08:00AM
Feb-21-20 10:34AM
Jan-23-20 09:07AM
Jan-08-20 08:00AM
Dec-06-19 09:25AM
Dec-05-19 09:42PM
Dec-04-19 12:00PM
Nov-26-19 08:00AM
Nov-25-19 02:11PM
Nov-21-19 11:30AM
Nov-15-19 07:00AM
Nov-08-19 08:00AM
Oct-29-19 06:47AM
Oct-16-19 02:29PM
Oct-15-19 08:00AM
Sep-25-19 08:00AM
Sep-14-19 09:36AM
Bio-Path Holdings, Inc. operates as a clinical and preclinical stage oncology focused RNAi nano particle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction. Its lead drug candidate is prexigebersen, which is in Phase II clinical trials for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome. It is also developing Liposomal Bcl-2 for the treatment of refractory/relapsed lymphoma and chronic lymphocytic leukemia; Liposomal STAT3 that is in preclinical stage for the treatment of pancreatic cancer, non-small cell lung cancer, and AML; and prexigebersen-A for various solid tumors. Bio-Path Holdings, Inc. was founded in 2007 and is based in Bellaire, Texas.